The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.
The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.
Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.
Daily Chart
(Technical analysis chart by Tech Trader)
Grok's Analysis - Grok 4
| 2025-11-24 | SOLD |
| 2025-11-21 | HOLD LONG |
|
Summary: Hold LONG on MRK as the confirmed uptrend continues with EMA above rising SMA, price surging above both to 98.26 on high volume and positive Keytruda momentum, maintaining position from 86.28 entry targeting 100.9 resistance amid no immediate catalysts....
|
|
| 2025-11-20 | HOLD LONG |
|
Summary: Hold LONG on MRK as the uptrend persists with EMA above SMA, both rising, price above both after high-volume surge to $97+ on positive Keytruda trial data, maintaining position from $86.28 entry targeting $100+ resistance, with no immediate catalysts....
|
|
| 2025-11-19 | HOLD LONG |
|
Summary: Hold LONG on MRK as the uptrend continues with EMA above SMA, both rising, price above both after high-volume surge to $97+ on positive Keytruda news, targeting $100+ resistance from $86.28 entry, no near-term catalysts....
|
|
| 2025-11-17 | HOLD LONG |
|
Summary: Hold LONG on MRK as the confirmed uptrend persists with EMA above SMA, both rising, price above both after high-volume breakout above $90 resistance to new highs near $93, supported by positive Keytruda trial momentum and no near-term catalysts, targeting $95+ from $86.28 entry....
|
|
| 2025-11-13 | HOLD LONG |
|
Summary: Hold LONG on MRK as the confirmed uptrend continues with EMA above SMA, both rising, price above both, recent breakout above $90 on high volume and positive Keytruda momentum, holding from $86.28 entry targeting $95+ amid no immediate catalysts....
|
|
| 2025-11-12 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend continues with EMA above SMA, price above both and rising, recent breakout above $85-87 resistance on high volume amid positive Keytruda trial news and no near-term catalysts, with 9-bar hold from $86.28 entry targeting $93+....
|
|
| 2025-11-11 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA, price above both and rising, recent breakout above $85 support on high volume amid positive Keytruda developments and no immediate catalysts, with hold period at 8 bars still early targeting $93+ resistance....
|
|
| 2025-11-10 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend continues with EMA above SMA, price above both and rising, recovering from $82 support amid positive Keytruda momentum and no near-term catalysts, with hold period still early....
|
|
| 2025-11-07 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA, price above both and recovering from $82 support without breaking lower, supported by positive Keytruda trial news and no imminent earnings, while hold period is short....
|
|
| 2025-11-06 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend continues with EMA above SMA and price recovering above both after a brief dip to $82 support without breaking key levels, supported by positive Keytruda trial momentum and no near-term earnings or catalysts, while minimum hold period remains unmet....
|
|
| 2025-11-05 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA, price recovering from a dip above key supports like $82 without breaking them, supported by positive Keytruda momentum and no immediate catalysts or earnings risks, while minimum hold period unmet....
|
|
| 2025-11-04 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend shows EMA above SMA with no major support breaks yet, positive Keytruda news supporting recovery, and minimum hold period not met despite recent dip to $83.67....
|
|
| 2025-11-03 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend remains intact with EMA above SMA despite price dip below, positive MACD, no broken key supports, and ongoing Keytruda momentum supporting recovery to $90+ over multi-week horizon....
|
|
| 2025-10-31 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the confirmed uptrend persists with EMA above SMA and price above both, positive MACD momentum, hammer candle at support, and bullish Keytruda news supporting multi-week upside to $90+ resistance despite no immediate catalysts....
|
|
| 2025-10-30 | BUY |
|
Summary: Recommend LONG on MRK due to confirmed uptrend with EMA above SMA and price above both moving upward, recovery above prior $85 support after earnings with neutral results but positive price reaction, and positive MACD signaling momentum for multi-week hold targeting $90+ resistance amid stable pharma sector and Keytruda momentum. This isn't chasing a high; it's buying into strength after a pullback to around $84 in mid-October, which held above rising trendline support near $80.33 and didn't breach key supports like $78.65 or $75.93. MACD is positive at 0.799 with the histogram narrowing but still supportive of bullish momentum, RSI at 53.59 is neutral avoiding overbought territory, and Stochastic %K at 71.44 suggests room to run without immediate reversal risks. Volume on the 10/30 up day was solid at 12.7M, though not capitulatory, aligning with a steady climb rather than volatile swings....
|
|
| 2025-10-29 | CASH |
|
Summary: Recommend CASH on MRK due to upcoming earnings on 10/30/2025 without meeting hold-through criteria, confirmed uptrend but no entry allowed right before catalyst, recent pullback from $90 highs amid patent concerns and sector volatility, awaiting post-earnings clarity for potential long on dip above $85 support....
|
|
| 2025-10-28 | CASH |
|
Summary: Recommend CASH on MRK due to upcoming earnings on 10/30/2025 in 2 days, preventing new long entry despite confirmed uptrend with EMA above SMA, price above both, and both moving upward, while no strong catalysts justify risk and past trades show pullback vulnerabilities....
|
|
| 2025-10-27 | CASH |
|
Summary: Recommend CASH on MRK due to upcoming earnings on 10/30/2025 within 3 days, preventing new entry despite confirmed uptrend with EMA above SMA, price above both, positive MACD, and recent bounce from support near $85 targeting $90+....
|
|
| 2025-10-24 | CASH |
|
Summary: Recommend CASH on MRK as the confirmed uptrend shows recovery above EMA/SMA with positive MACD and RSI, but upcoming earnings on 10/30/2025 prevent entry given minimum hold requirements and failure to meet hold-through criteria, while no short allowed for pharma....
|
|
| 2025-10-23 | CASH |
|
Summary: Recommend CASH on MRK due to confirmed uptrend but upcoming earnings on 10/30/2025 preventing a minimum 10-14 day hold without violating no-hold-through-earnings rule, recent recovery from pullback lacking new catalysts for immediate re-entry after 10/15 exit, and no high-confidence long setup at current levels near resistance. However, the next earnings date is 10/30/2025, and historical data doesn't meet the thresholds for holding long through it (no surprises >=7% in at least 2 of last 4 quarters, average reaction ~0.08% <0.5%). This means any new long entry now would require exiting by 10/29 to avoid holding through, resulting in a hold of only about 6-7 days, which falls short of the required minimum 10-14 day horizon for trades....
|
|
| 2025-10-22 | CASH |
|
Summary: Recommend CASH on MRK due to confirmed uptrend with EMA above SMA and price above both, but upcoming earnings on 10/30/2025 prevent new long entry as minimum hold period would require holding through without meeting surprise/reaction criteria, while recent pullback from $91 highs lacks fresh catalysts for immediate re-entry after 10/15 exit at $84.11....
|
|
| 2025-10-21 | CASH |
|
Summary: Recommend CASH on MRK as the confirmed uptrend shows recovery from pullback with price above EMA/SMA, positive MACD, and neutral RSI, but upcoming earnings on 10/30/2025 pose high risk without meeting hold-through criteria, outweighing bullish Keytruda momentum for a new multi-week entry....
|
|
| 2025-10-20 | CASH |
|
Summary: Recommend CASH on MRK due to confirmed uptrend recovery to 86.4 but inability to hold required 10-14 days without violating exit before 10/30/2025 earnings, plus recent 10/15 exit at 84.11 without major new catalysts justifying quick re-entry....
|
|
| 2025-10-17 | CASH |
|
Summary: Recommend CASH on MRK due to confirmed uptrend with EMA above SMA and price above both, but upcoming earnings on 10/30/2025 prevent entry as minimum hold period would require holding through without meeting surprise criteria, while no high-conviction breakout or catalysts justify risk amid recent volatility....
|
|
| 2025-10-16 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price below both EMA and SMA despite EMA above SMA, avoiding new entries, especially with upcoming earnings on 10/30/2025 and no strong bullish catalysts outweighing recent breakdowns....
|
|
| 2025-10-15 | SOLD |
|
Summary: Exit LONG on MRK as the post-FDA breakout pullback has broken below the $85 support level without rebound, with price now under EMA in a weakening uptrend and MACD showing bearish momentum, cutting losses after 9-bar hold to avoid further downside ahead of 10/30/2025 earnings....
|
|
| 2025-10-14 | HOLD LONG |
|
Summary: MRK's MACD shows a bullish crossover with price above key moving averages, supported by positive momentum in recent news and upcoming earnings potential....
|
|
| 2025-10-13 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with price above EMA and SMA after Keytruda FDA approval breakout, viewing current pullback as a dip to support near $85 with potential rebound to $93 resistance before October 30 earnings exit. This pullback from the recent high around 90 follows a sharp breakout on high volume from late September, likely driven by positive FDA news on Keytruda's expanded approval for cervical cancer treatment, which I confirmed via recent news searches—classified as bullish due to credible regulatory backing, timeliness (announced early October), and potential for sustained market reaction through increased revenue projections....
|
|
| 2025-10-10 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend continues with price above EMA and SMA after Keytruda FDA approval breakout, despite short-term pullback, targeting resistance near $93 before exiting ahead of October 30 earnings....
|
|
| 2025-10-09 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with price above EMA and SMA following the Keytruda breakout, despite a pullback, targeting resistance around 93 before exiting ahead of October 30 earnings....
|
|
| 2025-10-08 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend remains intact with price above both EMA and SMA after the recent high-volume breakout on Keytruda FDA approval, despite a minor pullback to 86.61, targeting resistance near 93+ over the next few weeks before exiting ahead of October 30 earnings....
|
|
| 2025-10-07 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with price above EMA and SMA after high-volume breakout on Keytruda news, no breakdown yet despite minor pullback, targeting resistance near $93+ over multi-week hold before October 30 earnings....
|
|
| 2025-10-06 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the confirmed uptrend continues with EMA above SMA and price above both, supported by recent high-volume breakout on positive Keytruda FDA approval news, no technical breakdown or near-term catalysts to exit early....
|
|
| 2025-10-03 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the confirmed uptrend persists with EMA above SMA and price above both, following the sharp high-volume breakout on positive Keytruda FDA news, with no immediate technical breakdown or catalysts warranting exit after just 1 bar....
|
|
| 2025-10-02 | BUY |
|
Summary: Recommend LONG on MRK due to confirmed uptrend with EMA above SMA, price above both, sharp high-volume breakout above resistance on positive FDA news for Keytruda, targeting $95+ over multi-week hold despite upcoming earnings exit needed by 10/27....
|
|
| 2025-10-01 | CASH |
|
Summary: Recommend CASH on MRK as the trend remains unclear with EMA below SMA despite the price gap above both on high volume, avoiding new long entry without confirmed uptrend per technical rules, while no shorting pharma stocks....
|
|
| 2025-09-30 | CASH |
|
Summary: Recommend CASH on MRK as the trend remains unclear with EMA below SMA, frequent crossings in the past month without volume capitulation, and price in a range near resistance at $85.83 after a recent long exit on 9/12, avoiding new entry despite today's bounce....
|
|
| 2025-09-29 | CASH |
|
Summary: Recommend CASH on MRK due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, policy against shorting pharma stocks, and recent price action showing continued weakness without high-conviction reversal signals, targeting a multi-week hold only on better setups....
|
|
| 2025-09-26 | CASH |
|
Summary: Recommend CASH on MRK as the confirmed downtrend with EMA below SMA and price below both, lack of volume capitulation, and pharmaceutical nature prohibiting shorts outweigh any potential bullish news or setups for a multi-week hold....
|
|
| 2025-09-25 | CASH |
|
Summary: Recommend CASH on MRK as the chart shows a downtrend with EMA below SMA and price below both without volume capitulation, preventing long entry while shorting pharma stocks is avoided due to sudden news risk. MACD remains negative at -1.0525 with the histogram contracting, and Slow STO shows low momentum at K=1.94/D=5.10, reinforcing bearish pressure without reversal signals. Support sits at $75.93 with strong historical bounces, but current price at $77.83 is testing lower without breaking, and falling resistance trendlines from $83.79-$83.94 add overhead pressure, suggesting potential for further downside before any bounce....
|
|
| 2025-09-24 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear or down with EMA below SMA and price below both, no volume capitulation for long entry in downtrend, recent long exited at loss on 9/12, and avoiding re-entry soon without high-confidence bullish reversal signals near rising trendline support....
|
|
| 2025-09-23 | CASH |
|
Summary: Recommend CASH on MRK as technicals show an unclear trend with tightly bound EMA and SMA, price below both without volume capitulation, avoiding new entries while no high-confidence long or short setup exists amid pharmaceutical sector risks....
|
|
| 2025-09-22 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with EMA and SMA tightly rangebound without clear direction, price below both, no volume capitulation, and recent history of whipsaw losses from premature entries, while avoiding shorts on pharma stocks amid potential positive catalysts....
|
|
| 2025-09-19 | CASH |
|
Summary: Recommend CASH on MRK as the trend remains unclear with EMA slightly above SMA but price below both, frequent crossings in the past month without volume capitulation, and no high-confidence setup for entry despite neutral RSI and proximity to rising support near $79....
|
|
| 2025-09-18 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price below both EMA and SMA, no volume capitulation for a long entry, recent history of failed longs, and no high-conviction setup for a multi-week hold amid ranging price action. No recent volume capitulation flagged, so buying a dip here in what could be a downtrend risks further downside without confirmation. Resistance at $85.83 has capped upside multiple times recently, while support at $75.93 is farther down but has held in prior tests....
|
|
| 2025-09-17 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no recent volume capitulation to justify a dip buy in this setup, and recent pullback from resistance at $85.83 lacks bullish confirmation for a new long entry targeting multi-week hold....
|
|
| 2025-09-16 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no volume capitulation for a long entry in potential downtrend, and recent history shows failed longs on breakdowns without strong catalysts to justify a new position targeting multi-week hold....
|
|
| 2025-09-15 | CASH |
|
Summary: Recommend CASH on MRK due to unclear trend with EMA above SMA but price below both, recent long exit on 9/12 after breakdown below support at $83.36 with declining MACD, no volume capitulation for dip buying in potential downtrend, and lack of high-conviction bullish catalysts outweighing pharma sector volatility risks for a multi-week hold....
|
|
| 2025-09-12 | SOLD |
|
Summary: Recommend exiting LONG on MRK as price broke below key support at $83.36 with declining MACD momentum, neutral RSI at 48, and no strong bullish catalysts to sustain the uptrend targeting $85.83 resistance....
|
|
| 2025-09-11 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend continues with EMA above SMA and price above both, positive MACD momentum, neutral RSI around 55, no breakdowns below key supports like $83.36, and stable pharma sector with recent positive news on Keytruda expansions targeting resistance at $85.83 for further multi-week gains. Technicals are solid first: RSI at 55.66 is neutral, avoiding overbought territory; MACD at 0.5888 is below signal at 0.7002 but the histogram is narrowing positively from recent lows, suggesting building momentum after a pullback; Bollinger Bands are expanding slightly with price near the upper band, indicating potential for continuation. No volume capitulation flagged recently, but the lack of it supports avoiding shorts in this downtrend-free setup. Key support at $83.36 (strength 2, recently tested) held firm, while resistance at $85.83 (strength 4) is being approached—historical patterns show MRK often breaks or consolidates here before pushing higher, as seen in bounces from similar levels in March-May 2025 without immediate reversals....
|
|
| 2025-09-10 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA and price above both, positive MACD momentum building, neutral RSI, no breakdowns below key supports, and stable pharma sector amid recent positive drug trial rumors targeting resistance at $85.83 for multi-week gains. Technicals are solid first: RSI at 51.34 is neutral, avoiding overbought territory; MACD at 0.564 is below the signal at 0.727 but showing convergence toward a potential bullish crossover, supported by recent positive histogram shifts; Bollinger Bands are narrowing (upper 86.58, lower 82.39), suggesting reduced volatility and a possible squeeze higher. Volume on 9/10 was lower at 6.44M, but recent up days like 8/21-8/22 had higher volume on gains, indicating buying interest....
|
|
| 2025-09-09 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the confirmed uptrend continues with EMA above SMA and price above both, positive MACD momentum, neutral RSI, and no immediate catalysts or breakdowns, targeting potential breakout above $85.83 resistance for multi-week gains amid stable pharma sector trends. The price is approaching the key resistance at $85.83 (strength 4, recently tested), but there's no sign of breakdown yet, supported by a positive MACD (0.6313) that's improving despite being slightly below its signal line (0.7663), and RSI at 53.72 remaining neutral, avoiding overbought conditions. Volume has been steady without capitulation flags, and the rising support trendline at ~$78.60 provides a buffer, with historical bounces suggesting resilience in similar setups....
|
|
| 2025-09-08 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA and price above both, nearing $85.83 resistance without breakdown, supported by positive MACD crossover and neutral RSI amid stable pharma sector trends. There's no sign of trend reversal like EMA/SMA crossover or price sustaining below both, and the absence of recent volume capitulation means we avoid forcing an exit. MACD is positive at 0.6565 with signal at 0.7986, indicating building momentum, while RSI at 51.77 is neutral, avoiding overbought conditions that might prompt selling....
|
|
| 2025-09-05 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the confirmed uptrend continues with EMA above SMA and price above both, no exit signal despite nearing $85.83 resistance, supported by positive MACD, neutral RSI, and stable pharma sector without immediate catalysts....
|
|
| 2025-09-04 | HOLD LONG |
|
Summary: Recommend holding LONG on MRK as the uptrend persists with EMA above SMA and price above both, recent dip to 83.96 from 84.18 entry offers no exit signal near $85.83 resistance, supported by positive MACD and neutral RSI targeting $90+ amid stable pharma outlook. Volume has been steady without capitulation flags, and the price is holding above the rising trendline support around $78.40, with key support at $75.93 far below. Resistance at $85.83 is nearby but not yet tested on this pullback, aligning with the prior exit strategy of selling near resistance after the previous gain from $84.21 to $85.48....
|
|
| 2025-09-03 | BUY |
|
Summary: Recommend LONG on MRK due to confirmed uptrend with EMA above SMA and price above both, dip to 84.35 offering better re-entry than recent 85.48 exit after pullback from $85.83 resistance, with neutral RSI and positive MACD supporting multi-week hold targeting $90+ amid stable pharma sector and no immediate catalysts....
|
|
| 2025-09-02 | SOLD |
|
Summary: Exit LONG on MRK as price nears $85.83 resistance in uptrend with EMA above SMA and positive MACD, but RSI neutral and no strong catalysts to break higher, locking in gains after 11-bar hold from $84.21 entry amid stable pharma sector....
|
|
| 2025-08-29 | HOLD LONG |
|
Summary: Hold LONG on MRK as uptrend persists with EMA above SMA, price above both, positive MACD, neutral RSI, holding above $78-83 support, targeting $85-90 resistance amid bullish pharma news and no near-term catalysts....
|
|
| 2025-08-28 | HOLD LONG |
|
Summary: Hold LONG on MRK as the uptrend continues with EMA above SMA and price above both, bullish MACD crossover, neutral RSI, support holding at $78-83 levels without breakdown, and no immediate catalysts or earnings risks, targeting resistance near $85-90....
|
|
| 2025-08-27 | HOLD LONG |
|
Summary: Hold LONG on MRK as the uptrend persists with EMA above SMA and price above both, bullish MACD, neutral RSI, recent support holds at rising trendlines near $83-84, and no breakdowns or near-term catalysts, targeting $90+ resistance....
|
|
| 2025-08-26 | HOLD LONG |
|
Summary: Hold LONG on MRK as the uptrend remains confirmed with EMA above SMA and price above both, positive MACD crossover, neutral RSI, recent break above $85.83 resistance holding, and no immediate breakdowns or catalysts signaling reversal, targeting $90+....
|
|
| 2025-08-25 | HOLD LONG |
|
Summary: Continue holding LONG on MRK as the confirmed uptrend persists with EMA above SMA and price above both, recent highs pushing past $85.83 resistance on positive MACD, neutral RSI, and no breakdowns or immediate catalysts, targeting $90+ over weeks....
|
|
| 2025-08-22 | HOLD LONG |
|
Summary: Continue holding LONG on MRK as the uptrend persists with EMA above SMA and price above both, recent breakout above $85.83 resistance on high volume, positive MACD crossover, and no immediate catalysts or breakdowns, targeting $90+ over multi-week horizon....
|
|
| 2025-08-21 | HOLD LONG |
|
Summary: Continue holding LONG on MRK as the uptrend remains intact with EMA above SMA and price above both, positive MACD divergence, and recent highs testing resistance at $85.83 without breakdown, supporting a multi-week hold targeting $90+ amid no immediate catalysts....
|
|
| 2025-08-20 | HOLD LONG |
|
Summary: Continue holding LONG on MRK as the uptrend persists with EMA above SMA and price above both, recent price action testing resistance at $85.83 with positive MACD momentum and no breakdowns or near-term catalysts warranting exit....
|
|
| 2025-08-19 | HOLD LONG |
|
Summary: Continue holding LONG on MRK as the uptrend remains confirmed with EMA above SMA and price above both, recent close at $85.06 pushing towards resistance at $85.83 amid rising momentum and no immediate breakdowns or catalysts for exit....
|
|
| 2025-08-18 | HOLD LONG |
|
Summary: Recommend continuing LONG on MRK as the confirmed uptrend persists with EMA above SMA and price above both, recent close at $84.31 slightly above entry with no breakdown of rising trendline support near $81, targeting resistance at $85.83+ amid neutral RSI and lack of immediate catalysts for exit....
|
|
| 2025-08-15 | BUY |
|
Summary: Recommend LONG on MRK as it's in a confirmed uptrend with EMA above SMA, price above both, RSI neutral at 60 avoiding overbought, and recent high-volume bounce from rising trendline support near $81 targeting resistance at $85.83+ for multi-week hold....
|
|
| 2025-08-14 | CASH |
|
Summary: MRK is in a confirmed uptrend with EMA above SMA and price above both, but after recent losing longs exited at $79.86, current price at $82.80 is higher, so avoiding re-entry to wait for a dip while no shorting pharma stocks....
|
|
| 2025-08-13 | CASH |
|
Summary: MRK is in an uptrend with EMA above SMA and price above both, but the current level at 82.78 isn't a dip after recent exit at 79.86 loss, so stay patient for a better entry on pullback to support near 80.2 trendline....
|
|
| 2025-08-12 | CASH |
|
Summary: Trend is unclear with EMA slightly above SMA but price below both, tightly rangebound averages, recent long trades failed with losses, no volume capitulation or strong bullish catalysts, so stay in cash for better setup....
|
|
| 2025-08-11 | CASH |
|
Summary: Staying in cash due to unclear trend with price below both EMA and SMA despite EMA above SMA, no volume capitulation, recent long trade losses, and no high-confidence setup for entry....
|
|
| 2025-08-08 | CASH |
|
Summary: Recommend CASH on MRK as the trend remains unclear with price fluctuating around tightly bound EMA and SMA without clear crossings but frequent price penetrations, no volume capitulation, and recent post-earnings volatility leading to prior losing longs, suggesting patience for a high-confidence setup targeting multi-week holds....
|
|
| 2025-08-07 | CASH |
|
Summary: Recommend CASH on MRK as the trend remains unclear with frequent price crossings of EMA and SMA without volume capitulation, recent losses from failed long entries advise patience, and no high-confidence setup for long or short given pharmaceutical sector restrictions and mixed news on restructuring and pipeline concerns....
|
|
| 2025-08-06 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, recent long trades ended in losses due to breakdowns below supports, and no volume capitulation or immediate bullish catalysts support a new entry. Over the past month, the stock has experienced volatility post-Q2 earnings on 7/29, with a sharp drop from around 84 to 78, followed by a modest recovery that failed to sustain above key levels, mirroring the failed long entries in the trade history where we exited at losses after breakdowns....
|
|
| 2025-08-05 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with price frequently crossing the EMA in the past month without volume capitulation, recent long trades resulted in losses on failed bounces, and no high-confidence dip in a confirmed uptrend for entry, while avoiding shorts on pharma stocks....
|
|
| 2025-08-04 | SOLD |
|
Summary: Exit LONG on MRK as price drops below both EMA and SMA in unclear trend with bearish MACD crossover, failing to sustain post-earnings bounce from rising trendline support near $77 amid mixed Q2 results showing revenue decline and Keytruda patent concerns, to cut losses and await clearer setup....
|
|
| 2025-08-01 | HOLD LONG |
|
Summary: Hold LONG on MRK as price bounces from rising trendline support near $76.86 after post-earnings dip to $77.58, with unclear trend but positive MACD crossover, neutral RSI at 43, and strong Keytruda sales amid revised FY25 guidance targeting resistance at $85.83 for multi-week recovery....
|
|
| 2025-07-31 | HOLD LONG |
|
Summary: Hold LONG on MRK despite post-earnings pullback to 78.53 below entry at 82.63, as price nears rising trendline support around 76.79 with no volume capitulation, unclear trend per EMA/SMA, positive MACD, neutral RSI at 40, and Keytruda strength amid raised FY25 guidance targeting resistance at 85.83 for multi-week recovery....
|
|
| 2025-07-30 | HOLD LONG |
|
Summary: Hold LONG on MRK as the recent entry follows a post-earnings bounce from rising trendline support around $76.73 with positive MACD, neutral RSI at 49, and raised FY25 guidance despite revenue miss and restructuring, targeting resistance near $85.83 amid Keytruda strength for a multi-week hold....
|
|
| 2025-07-29 | BUY |
|
Summary: Recommend LONG on MRK after post-earnings bounce from rising trendline support at $76.67 in confirmed uptrend, with positive MACD crossover, neutral RSI, raised FY25 outlook despite cost cuts, and high-volume recovery targeting resistance near $85.83 for multi-week hold....
|
|
| 2025-07-28 | CASH |
|
Summary: Stay in cash due to upcoming earnings on July 29, 2025, and recent price run-up without a clear dip in the uptrend, following a quick loss on previous long entry at $81.52 sold at $79.96....
|
|
| 2025-07-25 | CASH |
|
Summary: Recommend CASH on MRK due to upcoming Q2 earnings on July 29 risking volatility after recent uptrend from $73 lows, unclear catalysts like Keytruda patent concerns, and avoiding re-entry higher post-loss exit at $79.96 for a multi-week hold....
|
|
| 2025-07-24 | CASH |
|
Summary: Recommend CASH on MRK as the uptrend continues but price is near recent highs without a dip for entry, recent loss exit advises patience, and potential earnings risk looms with Keytruda concerns....
|
|
| 2025-07-23 | CASH |
|
Summary: Recommend CASH on MRK due to clear uptrend but upcoming Q2 earnings on July 29th risking volatility, recent failed long entry, and price nearing resistance at $85.83 without strong catalysts for a multi-week hold....
|
|
| 2025-07-22 | CASH |
|
Summary: Recommend CASH on MRK due to recent long exit at a loss on 7/18/2025, price now higher at 81.67 avoiding re-entry per patience rule, uptrend present but upcoming earnings on 7/30/2025 risking volatility without strong bullish catalysts outweighing historical post-earnings drops....
|
|
| 2025-07-21 | CASH |
|
Summary: Recommend CASH on MRK as the trend is unclear with EMA above SMA but price between them, recent volume capitulation prevents shorting, no strong uptrend for longing, and we just exited a losing long position, warranting patience for a better entry....
|
|
| 2025-07-18 | SOLD |
|
Summary: Recommend CASH on MRK as the price broke below the rising trendline support at $80.39 with a bearish MACD crossover on declining momentum, invalidating the prior long entry at $81.52 for a multi-week hold while no new bullish catalysts emerged to support recovery....
|
|
| 2025-07-17 | BUY |
|
Summary: Recommend LONG on MRK due to bullish MACD crossover, rising trendline support at $80, RSI neutral at 52 avoiding overbought, recent climb from $73 lows with high-volume bounces, and positive catalysts like Keytruda expansions outweighing range resistance at $85.83 for a multi-week hold targeting $90+....
|
|